OraSure Technologies Inc
orasure.comWhat Do They Do?
Sells rapid diagnostic tests and sample-collection devices to healthcare and public health organizations, research and commercial customers, and consumers.
10-K for FY2025, filed Mar 9, 2026The Company's business consists of the development, manufacture, marketing, sale and distribution of simple, easy to use diagnostic…View ↗
The Company's business also includes sample management solutions and services that are used by clinical laboratories, direct-to-consumer…View ↗
The Company sells genomic products that provide all-in-one systems for the collection, stabilization, transportation, and storage of DNA…View ↗
How Do They Make Money?
Customers buy diagnostic tests and sample-collection products, generally paying 30 to 120 days after shipment. Other revenue includes royalties when licensees sell products and research funding tied to work performed.
10-K for FY2025, filed Mar 9, 2026Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that…View ↗
Other revenues. Other revenues consist primarily of royalty income and funding from grants of research and development efforts. Royalties…View ↗
Financing and payment. The Company's payment terms vary by the type and location of the customer and products or services offered. Payment…View ↗
-
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗
$115M
-
10-K for FY2025, filed Mar 9, 2026
$115M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Products and services
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
95%
FY2022: 98%
|
Products and services, FY2025
$109.1M Sources
|
Sold outright |
|
Other
|
5.2%
FY2022: 2.4%
|
Other, FY2025
$6M Sources
|
Who Are Their Customers?
Healthcare providers, public health and government groups, consumers, and research and commercial customers buy diagnostic tests and collection products. Sales reach them through direct sales, strategic arrangements, and independent distributors.
10-K for FY2025, filed Mar 9, 2026The Company's business consists of the development, manufacture, marketing, sale and distribution of simple, easy to use diagnostic…View ↗
The Company's business also includes sample management solutions and services that are used by clinical laboratories, direct-to-consumer…View ↗
Sales and MarketingView ↗
10-K for FY2025, filed Mar 9, 2026
One non-commercial customer accounted for approximately 3% of the Company's consolidated net revenues for the year ended December 31, 2025…View ↗
Do Revenues Turn Into Profits?
No. It lost $68.7M in FY2025.
10-K for FY2025, filed Mar 9, 2026
−$72MView ↗
10-K for FY2025, filed Mar 9, 2026
−$68.7MView ↗
10-K for FY2025, filed Mar 9, 2026
−$53.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
$6.2MView ↗
- ▲ Now profitable
- vs −$19.7M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 7, 2026
Open tableView ↗
-
Aug 5, 2026
Gave third-quarter revenue guidance of $29.5 million to $32.5 million
Sources
8-K, filed Aug 5, 2026
The Company is guiding to Q3 2026 total revenues of $29.5 million to $32.5 million.View ↗
-
May 6, 2026
Gave second-quarter revenue guidance of $27 million to $30 million
Sources
8-K, filed May 6, 2026
The Company is guiding to Q2 2026 Total revenues of $27 million to $30 million.View ↗
Shrinking. Revenue fell 51% in 4 years, from $233.7M in FY2021 to $115M in FY2025, about 16% a year.
Exit from lab services
Diversigen offered laboratory and analytical services for genomics and microbiome customers; OraSure later exited the molecular-services line.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Mar 9, 2026Our Molecular Solutions products include the Colli-Pee® device, developed and sold by our Novosanis subsidiary, for the volumetric…View ↗
Molecular Services revenues, which were largely derived from the Company's microbiome molecular sequencing services, were nil for the year…View ↗
Risk-assessment line discontinued
The earlier report described laboratory-processed drug-abuse tests; OraSure later discontinued its risk-assessment line, which included substance-abuse testing.
10-K for FY2022, filed Mar 3, 2023Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of simple, easy to use diagnostic products…View ↗
Loading...
